Evaluation of the Effects of Noscapine on the Treatment of Patients with COVID-19

Phase 3

Recruiting

Conditions: COVID-19 pneumonia.
COVID-19, virus identified
U07.1

Registration Number: IRCT20151227025726N31

Lead Sponsor: Shahid Beheshti University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 100

Inclusion Criteria

People over 18 years old
Patient with cough and positive RT-PCR for COVID-19 and candidate for outpatient treatment
The onset of illness equal to/less than 5 days

Exclusion Criteria

Pregnancy
Breastfeeding
Allergy to noscapine, morphine or any of the components of the formulation
History of seizure
Diarrhea
Diabetes
Consumption of warfarin, benzodiazepines, opioid agonists
Getting antitussive drugs

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Time required to respond to treatment. Timepoint: Daily until discharge. Method of measurement: VAS scale.;Time required to resolve cough. Timepoint: Daily until discharge. Method of measurement: Patient history.;Intensity of cough. Timepoint: Daily until discharge. Method of measurement: CSS score.

Secondary Outcome Measures

Name	Time	Method
Quality of Life. Timepoint: Before the start of the study and at the end of the study. Method of measurement: CQLQ questionnaire.;Blood oxygen level. Timepoint: Before the start of the study and at the end of the study. Method of measurement: Pulse oximeter.;Shortness of breath. Timepoint: Before the start of the study and at the end of the study. Method of measurement: Patient history.